{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:15:32Z","timestamp":1790741732166,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.euf.2017.06.008","type":"journal-article","created":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T09:17:15Z","timestamp":1498900635000},"page":"81-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Risk of Testosterone Flare in the Era of the Saturation Model: One More Historical Myth"],"prefix":"10.1016","volume":"5","author":[{"given":"Yonah","family":"Krakowsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Morgentaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2017.06.008_bib0005","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.eururo.2006.06.034","article-title":"Testosterone and prostate cancer: a historical perspective on a modern myth","volume":"50","author":"Morgentaler","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2017.06.008_bib0010","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1056\/NEJM198908173210701","article-title":"Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide)","volume":"321","author":"Kuhn","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2017.06.008_bib0015","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0022-5347(05)66353-7","article-title":"The gonadotropin-releasing hormone antagonist abarelix deport versus luteinizing hormone releasing hormone agonist leuprolide or goserelin: initial result of the endocrinological and biochemical efficacies in patients with prostate cancer","volume":"165","author":"Tomera","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2017.06.008_bib0020","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1002\/cncr.25975","article-title":"Turning conventional wisdom upside-down","volume":"117","author":"Morgentaler","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2017.06.008_bib0025","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.eururo.2015.12.005","article-title":"Testosterone therapy in men with prostate cancer","volume":"69","author":"Kaplan","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2017.06.008_bib0030","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2013.08.015","article-title":"A new era of testosterone and prostate cancer: from physiology to clinical implications","volume":"65","author":"Khera","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2017.06.008_bib0035","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.eururo.2008.09.024","article-title":"Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth","volume":"55","author":"Morgentaler","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2017.06.008_bib0040","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0022-5347(01)65871-3","article-title":"The effect of exogenous testosterone on total and free prostate specific antigen levels in healthy young men","volume":"156","author":"Cooper","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2017.06.008_bib0045","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.juro.2011.04.065","article-title":"Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory","volume":"186","author":"Khera","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2017.06.008_bib0050","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.clinthera.2010.04.013","article-title":"Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: A phase III, open-label, international multicenter study","volume":"32","author":"Marberger","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.euf.2017.06.008_bib0055","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/jjco\/29.11.562","article-title":"Goserelin acetate with or without antiandrogen or estrogen in the treatment of patients with advanced prostate cancer: a multicenter, randomized, controlled trial in Japan","volume":"29","author":"Kotake","year":"1999","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.euf.2017.06.008_bib0060","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/PL00012076","article-title":"Inhibition of PSA flare in prostate cancer patients by administration of flutamide for 2 weeks before initiation of treatment with slow-releasing LH-RH agonist","volume":"6","author":"Noguchi","year":"2001","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.euf.2017.06.008_bib0065","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000056592","article-title":"Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist","volume":"66","author":"Tsushima","year":"2001","journal-title":"Urol Int"},{"key":"10.1016\/j.euf.2017.06.008_bib0070","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/BF02564863","article-title":"Influence of luteinizing hormone-releasing hormone analogues on serum levels of prostatic acid phosphatase and prostatic specific antigen in patients with metastatic carcinoma of the prostate","volume":"30","author":"Sasagawa","year":"1998","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.euf.2017.06.008_bib0075","first-page":"271","article-title":"A long term follow-up of patients with advanced prostatic cancer treated with buserelin","volume":"185A","author":"Waxman","year":"1985","journal-title":"Prog Clin Biol Res"},{"key":"10.1016\/j.euf.2017.06.008_bib0080","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.1987.5.6.912","article-title":"Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer","volume":"5","author":"Ahmann","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2017.06.008_bib0085","first-page":"41","article-title":"A comparison between surgical orchidectomy and the LHRH agonist Zoladex (ICI 188630) in the treatment of metastatic cancer of the prostate","volume":"303","author":"Peeling","year":"1989","journal-title":"Prog Clin Biol Res"},{"key":"10.1016\/j.euf.2017.06.008_bib0090","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0022-5347(17)45620-5","volume":"135","author":"de Voogt","year":"1986","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2017.06.008_bib0095","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0022-5347(17)54531-0","article-title":"The response of metastatic adenocarcinoma of the prostate to exogenous testosterone","volume":"126","author":"Fowler","year":"1981","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2017.06.008_bib0100","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/S0022-5347(17)39774-4","article-title":"Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate","volume":"144","author":"Thompson","year":"1990","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2017.06.008_bib0105","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2017.06.008_bib0110","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/jnci\/djm323","article-title":"Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies","volume":"100","author":"Endogenous Hormones and Prostate Cancer Collaborative Group","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euf.2017.06.008_bib0115","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/pcan.2013.60","article-title":"The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis","volume":"17","author":"Cui","year":"2014","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euf.2017.06.008_bib0120","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.juro.2013.02.002","article-title":"Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy","volume":"190","author":"Pastuszak","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2017.06.008_bib0125","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/bju.12668","article-title":"Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer","volume":"114","author":"Balbontin","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2017.06.008_bib0130","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.juro.2015.05.084","article-title":"Testosterone therapy after radiation therapy for low, intermediate and high risk prostate cancer","volume":"194","author":"Pastuszak","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2017.06.008_bib0135","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4103\/1008-682X.160270","article-title":"Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results","volume":"18","author":"Kacker","year":"2016","journal-title":"Asian J Androl"},{"key":"10.1016\/j.euf.2017.06.008_bib0140","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.urolonc.2014.04.016","article-title":"Risk of disease flare with LHRH agonist therapy in men with prostate cancer: myth or fact?","volume":"33","author":"Vis","year":"2015","journal-title":"Urol Oncol"},{"issue":"Suppl 3","key":"10.1016\/j.euf.2017.06.008_bib0145","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000463976","article-title":"A multicenter trial comparing the luteinizing hormone releasing hormone analog Zoladex, with Zoladex plus flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group","volume":"18","author":"Lunglmayr","year":"1990","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2017.06.008_bib0150","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1056\/NEJM198908173210702","article-title":"A controlled trial of leuprolide with and without flutamide in prostatic carcinoma","volume":"321","author":"Crawford","year":"1989","journal-title":"N Engl J Med"},{"issue":"12 Suppl","key":"10.1016\/j.euf.2017.06.008_bib0155","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1002\/1097-0142(19931215)72:12+<3880::AID-CNCR2820721724>3.0.CO;2-4","article-title":"Combination treatment in M1 prostate cancer","volume":"72","author":"Ferrari","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2017.06.008_bib0160","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1056\/NEJM198411153112004","article-title":"Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group","volume":"311","author":"The Leuprolide Study Group","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2017.06.008_bib0165","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1002\/1097-0142(19851115)56:10<2416::AID-CNCR2820561013>3.0.CO;2-#","article-title":"Buserelin as primary therapy in advanced prostatic carcinoma","volume":"56","author":"Presant","year":"1985","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2017.06.008_bib0170","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1136\/bmj.291.6506.1387","article-title":"Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer","volume":"291","author":"Waxman","year":"1985","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"Suppl 2","key":"10.1016\/j.euf.2017.06.008_bib0175","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1097\/00000421-198801102-00031","article-title":"Zoladex treatment of symptomatic prostatic carcinoma","volume":"11","author":"Holdaway","year":"1988","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.euf.2017.06.008_bib0180","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0149-2918(96)80215-3","article-title":"Leuprolide acetate 22.5mg 12-week depot formulation in the treatment of patients with advanced prostate cancer","volume":"18","author":"Sharifi","year":"1996","journal-title":"Clin Ther"},{"key":"10.1016\/j.euf.2017.06.008_bib0185","first-page":"279","article-title":"Treatment of metastatic carcinoma of the prostate with leuprolide, an LHRH analogue","volume":"185A","author":"Smith","year":"1985","journal-title":"Prog Clin Biol Res"},{"key":"10.1016\/j.euf.2017.06.008_bib0190","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0090-4295(87)90150-6","article-title":"Zoladex (ICI 118,630): clinical trial of new luteinizing hormone-releasing hormone analog in metastatic prostatic carcinoma","volume":"29","author":"Murphy","year":"1987","journal-title":"Urology"},{"key":"10.1016\/j.euf.2017.06.008_bib0195","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0090-4295(97)00500-1","article-title":"Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer","volume":"51","author":"Sharifi","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.euf.2017.06.008_bib0200","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0022-5347(05)00161-8","article-title":"A 12-month clinical study of LA-2585 (45.0mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer","volume":"175","author":"Crawford","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2017.06.008_bib0205","doi-asserted-by":"crossref","first-page":"477","DOI":"10.5114\/aoms.2014.43743","article-title":"Efficacy and tolerability of 1- and 3-month leuprorelin acetate depot formulations (Eligard(\u00ae)\/Depo-Eligard(\u00ae)) for advanced prostate cancer in daily practice: a Belgian prospective non-interventional study","volume":"10","author":"Braeckman","year":"2014","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.euf.2017.06.008_bib0210","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/pcan.2008.52","article-title":"Safety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe","volume":"12","author":"Tunn","year":"2009","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euf.2017.06.008_bib0215","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0022-5347(05)64625-3","article-title":"A clinical study of 22.5mg. La-2550: a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer","volume":"168","author":"Chu","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2017.06.008_bib0220","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/S0149-2918(02)80087-X","article-title":"A six-month, open-label study assessing a new formulation of leuprolide 7.5mg for suppression of testosterone in patients with prostate cancer","volume":"24","author":"Perez-Marreno","year":"2002","journal-title":"Clin Ther"},{"key":"10.1016\/j.euf.2017.06.008_bib0225","first-page":"1168","article-title":"Efficacy and safety of leuprorelin acetate 6-month depot in prostate cancer patients: a Phase III, randomized, open-label, parallel-group, comparative study in Japan","volume":"45","author":"Suzuki","year":"2015","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.euf.2017.06.008_bib0230","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.urology.2009.08.008","article-title":"Does oral antiandrogen use before luteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare?","volume":"75","author":"Oh","year":"2010","journal-title":"Urology"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456917301591?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456917301591?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:48:48Z","timestamp":1762498128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456917301591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S2405456917301591"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2017.06.008","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of Testosterone Flare in the Era of the Saturation Model: One More Historical Myth","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2017.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}